Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Exposure-response model for the effect of AZD5069, a novel CXCR2 antagonist, on neutrophil count in asthma patients
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Poster
- By: WAHLBY HAMREN, Ulrika (AstraZeneca R&D, Early Clinical Development, Mölndal, Sweden)
- Co-author(s): Ulrika Wahlby Hamren: Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
Justin Wilkins: Occams, Amstelveen, Netherlands;, SGS Exprimo NV, Mechelem, Belgium
Bengt Larsson: RIA TMU, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
Marie Cullberg: Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
BackgroundsAZD5069 is a reversible oral CXCR2 antagonist that blocks neutrophil migration and reduces circulating neutrophil counts . Models describing neutrophil dynamics after cytotoxic drug intervention have previously been published , however these are not applicable for the CXCR2 mechanism of action.
AimsWe developed a population.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019